Results 11 to 20 of about 25,289 (245)
The Journal of Clinical Hypertension, 2021 We tested our hypothesis that, in hypertensive patients with higher nocturnal home systolic blood pressure (HSBP) at baseline, a valsartan/cilnidipine (80/10 mg) combination would reduce nocturnal HSBP more markedly than a valsartan/hydrochlorothiazide ...
Takeshi Fujiwara +4 more
doaj +1 more source
Dose-Response, 2021 It has been proven a close relationship between intestinal microbiota and hypertension. Valsartan is a widely used ARB antihypertensive drug; so far, the effect of valsartan on intestinal microbiota remains largely unexplored.
Ying-Zi Qi +5 more
doaj +1 more source
PLoS ONE, 2022 ObjectiveHeart failure (HF) and atrial fibrillation (AF) are often coexisting. They have common risk factors and pathophysiologic mechanisms. Sacubitril/valsartan has shown efficacy and tolerability in patients with HF.
Xuehui Liu +4 more
doaj +2 more sources
EFFECT OF SACUBITRIL/VALSARTAN ON NATRIURESIS, DIURESIS AND BLOOD PRESSURE IN HYPERTENSIVE PATIENTS
Рациональная фармакотерапия в кардиологии, 2017 Aim. To study the effect of sacubitril/valsartan compared with valsartan on natriuresis, diuresis, blood pressure (BP) and the level of biomarkers in hypertensive patients.Material and methods.
Zh. D. Kobalava +3 more
doaj +1 more source
Clinical utility of valsartan in the treatment of hypertension in children and adolescents [PDF]
, 2011 Rossana Baracco, Gaurav KapurChildren’s Hospital of Michigan/Wayne State University, Detroit, MI, USAAbstract: Valsartan is a potent antagonist of the type 1 angiotensin receptor (AT1).
Gaurav Kapur, Rossana Baracco
core +1 more source
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018 BackgroundThere is a paucity of data about the mechanisms by which sacubitril/valsartan (also known as LCZ696) improves outcomes in patients with heart failure. Specifically, the effects of sacubitril/valsartan on vascular function and NO bioavailability
Rishi K. Trivedi +7 more
doaj +1 more source
Pharmaceutics, 2020 Background: Portal hypertension is characterized by exaggerated activation of the renin-angiotensin-aldosterone axis. Natriuretic peptide system plays a counter-regulatory role, which is modulated by neprilysin.
Shao-Jung Hsu +6 more
doaj +1 more source
Biomedicines, 2022 This study investigated whether sacubitril/valsartan and ivabradine are able to prevent left ventricular (LV) fibrotic remodelling and dysfunction in a rat experimental model of spontaneous hypertension (spontaneously hypertensive rats, SHRs) and whether
Fedor Simko +9 more
doaj +1 more source
Psychiatry and Clinical Psychopharmacology, 2021 Severe depression with suicidal ideation associated with the use of the valsartan , an angiotensin receptor antagonist, is reported. The patient, who was unresponsive to antidepressant medication with two different groups, dramatically recovered ...
Numan Konuk, Mustafa Aydın, Ömer Akay
doaj
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/valsartan, a first‐in‐class angiotensin receptor neprilysin inhibitor, received US Food and Drug Administration approval in 2015 for heart failure with reduced ejection fraction (HFrEF).
April F. Mohanty +14 more
doaj +1 more source